Onconova therapeutics, inc. (ONTX)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Dec'12
Assets
Current assets:
Cash and cash equivalents

31,036

22,726

4,821

5,882

10,396

16,970

22,384

29,540

7,264

4,024

-

-

-

21,450

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

7,600

14,989

15,389

-

25,778

12,818

16,835

19,799

22,197

25,358

33,698

43,582

42,348

55,499

54,624

60,009

76,612

51,181

81,527

Receivables

45

98

23

1,714

35

35

24

72

477

59

57

233

126

31

904

2,147

1,368

1,504

1,535

-

-

132

-

-

-

-

-

-

-

Marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14,999

14,997

29,999

39,994

39,990

-

-

Prepaid expenses and other current assets

795

650

957

833

759

760

696

545

814

820

1,000

711

848

1,588

1,168

975

1,153

1,832

1,902

2,017

2,605

3,066

4,278

3,331

4,401

4,387

5,326

5,867

1,725

Restricted cash

-

-

-

-

-

-

-

-

-

-

50

50

50

-

50

50

50

50

50

50

50

125

-

-

-

-

-

-

-

Total current assets

31,876

23,474

5,801

8,429

11,190

17,765

23,104

30,157

8,555

4,903

8,707

15,983

16,413

23,069

27,900

15,990

19,406

23,185

25,684

27,425

36,353

46,905

61,625

73,827

89,024

104,390

121,928

57,048

83,252

Property and equipment, net

47

50

54

1

1

9

20

34

48

64

83

105

129

152

176

200

224

248

273

300

348

420

512

609

557

626

652

729

463

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

125

125

125

125

125

125

125

Other non-current assets

150

150

150

150

150

149

12

12

12

12

12

12

12

12

12

12

12

12

12

12

12

12

12

12

12

12

12

12

12

Total assets

32,073

23,674

6,005

8,580

11,341

17,923

23,136

30,203

8,615

4,979

8,802

16,100

16,554

23,233

28,088

16,202

19,642

23,445

25,969

27,737

36,713

47,337

62,274

74,573

89,718

105,153

122,717

57,914

83,852

Liabilities and stockholders' equity
Current liabilities:
Accounts payable

4,183

4,271

4,524

4,750

4,334

4,039

4,264

5,949

7,034

6,186

5,436

5,681

5,407

5,323

4,071

2,801

3,296

3,421

3,190

4,185

3,857

4,027

5,385

5,027

3,302

3,710

4,405

4,410

5,517

Accrued expenses and other current liabilities

2,501

3,795

3,448

-

-

4,173

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses and other current liabilities

-

-

-

3,770

3,849

-

3,488

3,572

3,063

3,335

3,098

3,728

4,021

4,382

4,482

5,839

3,891

3,729

5,012

5,295

6,452

5,777

7,202

6,464

7,795

5,820

7,817

5,338

3,925

Deferred revenue

226

226

226

226

226

226

455

455

455

455

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

4

20

81

50

62

Option liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,967

Deferred revenue

-

-

-

-

-

-

-

-

-

-

455

455

455

455

455

455

455

455

455

455

455

455

455

455

455

788

2,530

3,509

3,907

Total current liabilities

6,910

8,292

8,198

8,746

8,409

8,438

8,207

9,976

10,552

9,976

8,989

9,864

9,883

10,160

9,008

9,095

7,642

7,605

8,657

9,935

10,764

10,259

13,042

11,947

11,556

10,338

14,833

13,307

25,378

Warrant liability

176

113

96

-

-

176

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrant liability

-

-

-

571

603

-

319

448

961

1,773

1,686

1,476

4,950

3,401

4,406

287

295

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue, non-current

3,639

3,695

3,752

3,809

3,865

3,922

3,750

3,864

3,977

4,091

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue, non-current

-

-

-

-

-

-

-

-

-

-

4,205

4,318

4,432

4,545

4,659

4,773

4,886

5,000

13,114

13,227

13,341

13,455

13,568

13,682

13,795

13,909

14,023

14,136

15,421

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

1

2

3

6

30

47

44

Total liabilities

10,725

12,100

12,046

13,126

12,877

12,536

12,276

14,288

15,490

15,840

14,880

15,658

19,265

18,106

18,073

14,155

12,823

12,605

21,771

23,162

24,105

23,715

26,611

25,631

25,354

24,253

28,886

27,490

40,843

Commitments and contingencies

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Redeemable convertible preferred stock, $0.01 par value per share, none and 18,548,253 shares authorized at December 31, 2013 and 2012, none and 16,912,199 issued and outstanding at December 31, 2013 and 2012

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

203,366

201,315

Stockholders' equity:
Preferred stock, $0.01 par value, 5,000,000 authorized at March 31, 2020 and December 31, 2019, none issued and outstanding at March 31, 2020 and December 31, 2019

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-

0

Common stock, $0.01 par value, 250,000,000 authorized at March 31, 2020 and December 31, 2019, 167,416,070 and 111,167,352 shares issued and outstanding at March 31, 2020 and December 31, 2019

1,674

1,112

82

60

59

57

57

851

194

8

99

99

68

68

68

27

274

25

237

217

217

217

217

217

217

215

214

26

26

Additional paid in capital

428,189

413,879

391,556

388,465

387,919

387,238

387,055

385,966

359,496

350,614

349,103

348,672

342,982

342,484

341,911

332,387

331,528

328,564

324,898

319,418

318,505

317,122

316,266

314,630

313,272

311,093

309,916

22,787

10,021

Accumulated other comprehensive loss

-24

-18

-27

-14

-18

-12

-7

-5

11

3

-1

-10

-26

-31

-17

-19

-16

-22

-18

-14

-43

-13

-8

-

-

1

-18

5

-

Accumulated deficit

-408,491

-403,399

-397,652

-393,057

-389,496

-381,896

-376,245

-370,897

-367,406

-362,316

-356,109

-349,149

-346,565

-338,224

-332,777

-331,178

-325,797

-318,557

-321,749

-315,876

-306,921

-294,578

-281,206

-266,328

-249,575

-230,896

-216,281

-195,760

-168,353

Total Onconova Therapeutics, Inc. stockholders' equity

-

-

-6,041

-4,546

-1,536

5,387

10,860

15,915

-7,705

-11,691

-6,908

-388

-3,541

4,297

9,185

1,217

5,989

10,010

3,368

3,745

11,758

22,748

35,269

48,519

63,914

80,413

93,831

-172,942

-158,306

Non-controlling interest

-

-

-

-

-

-

-

-

830

830

830

830

830

830

830

830

830

830

830

830

850

874

394

423

450

487

-

-

-

Total stockholders' equity

21,348

11,574

-6,041

-4,546

-1,536

5,387

10,860

15,915

-6,875

-10,861

-6,078

442

-2,711

5,127

10,015

2,047

6,819

10,840

4,198

4,575

12,608

23,622

35,663

48,942

64,364

80,900

-

-

-158,306

Total liabilities and stockholders' equity

32,073

23,674

6,005

8,580

11,341

17,923

23,136

30,203

8,615

4,979

8,802

16,100

16,554

23,233

28,088

16,202

19,642

23,445

25,969

27,737

36,713

47,337

62,274

74,573

89,718

105,153

122,717

57,914

83,852